- Sputnik International, 1920
World
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

UK Welcomes Russia's Candid Release of Sputnik V Results in The Lancet, Ambassador Says

© AP Photo / Zoltan BaloghA vial containing Russian vaccine Sputnik V is shown by a nurse at the South Pest Central Hospital in Budapest, Hungary, Friday, Feb. 12, 2021, as the vaccination with Sputnik V against the new coronavirus begins in the country.
A vial containing Russian vaccine Sputnik V is shown by a nurse at the South Pest Central Hospital in Budapest, Hungary, Friday, Feb. 12, 2021, as the vaccination with Sputnik V against the new coronavirus begins in the country. - Sputnik International, 1920, 25.02.2021
Subscribe
International
India
MOSCOW (Sputnik) - The publication of interim results of clinical trials of Russian coronavirus vaccine Sputnik V by the producers was welcomed in the United Kingdom as bolstering "transparency and access," UK Ambassador to Russia Deborah Bronnert said on Thursday.

The interim results of the Russian vaccine, developed by the Gamaleya Institute of Epidemiology and Microbiology, were published in the peer-reviewed medical journal The Lancet on 2 February.

"One thing that I do think was really welcome was that for Sputnik V, when the Russian institute, Gamaleya, put forward the results and got them published in The Lancet. It's not equivalent to approval but it's still a really welcome step forward in terms of transparency and access, and that's certainly something that we have been encouraging and welcome," Bronnert said at an event hosted by the Russo-British Chamber of Commerce.

To be used in the United Kingdom, Sputnik V would need to be approved "by our regulator or by a regulator that is equivalent," according to the diplomat.

Neither Gamaleya nor any other Russian vaccine producer has so far applied for the UK approval, the ambassador added.

© AP Photo / Eraldo PeresLaboratory workers work in the pilot production phase of Russia's Sputnik V Coronavirus vaccine for COVID-19 at the pharmaceutical company Uniao Quimica in Brasilia, Brazil, Monday, Jan. 25, 2021.
UK Welcomes Russia's Candid Release of Sputnik V Results in The Lancet, Ambassador Says - Sputnik International, 1920, 25.02.2021
Laboratory workers work in the pilot production phase of Russia's Sputnik V Coronavirus vaccine for COVID-19 at the pharmaceutical company Uniao Quimica in Brasilia, Brazil, Monday, Jan. 25, 2021.

Sputnik V is a human adenoviral platform-based vaccine, registered by the Russian government on 11 August last year. More than 35 other countries have approved and began using this vaccine to date, including Hungary, San Marino, Serbia, Argentina, Bolivia, Mexico, Nicaragua, Algeria, Lebanon and the United Arab Emirates.

Interim results from Sputnik's Phase 3 clinical trials, as published in The Lancet, established its efficacy at 91.6 percent.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала